<DOC>
	<DOCNO>NCT00193947</DOCNO>
	<brief_summary>Hypothesis Nevirapine resistance develop woman infant HIVNET 006 012 cohort consequence use agent long t½ monotherapy individual high viral load . Objective 1 To demonstrate Nevirapine resistance develop HIV infect patient use part triple antiretroviral combination therapy initiation treatment suppression HIV RNA &lt; 1000 copies/ml . Objective 2 To demonstrate resistance nevirapine develop patient suppress HIV RNA discontinue combination antiretroviral therapy contain nevirapine .</brief_summary>
	<brief_title>An Evaluation Development Nevirapine Induced Mutations HIV Patients Initiating Discontinuing Combination Antiretroviral Therapy</brief_title>
	<detailed_description>The HIVNET 012 clinical trial demonstrate cost effective strategy prevent maternal fetal transmission HIV . In study , single 200 mg dose Nevirapine give pregnant Ugandan woman onset labour single 2 mg/kg dose infant within 72 hour birth ( 1 ) . Given efficacy , simplicity low cost regime , World Health Organization recently recommend implementation regimen one several option prevention maternal fetal transmission HIV resource limit setting . Pharmacokinetic study demonstrate 200 mg Nevirapine give mother labour result concentration &gt; 100 mg/mL ( 10 time vitro IC50 ) newborn . Nevirapine elimination prolong mother infant median t½ 36.8 65.7 hour . Administration 200 mg orally mother single 2 mg/kg oral dose infant 48-72 hour , maintain serum concentration infant &gt; 100 mg/ml 7 day life ( 2 , 3 ) Early study demonstrate use Nevirapine monotherapy result rapid selection Nevirapine resistant mutation ( 4 ) . This associated loss antiviral activity return viral load baseline within 12 week . It appear soon non-nucleoside reverse transcriptase inhibitor drug low genetic barrier single mutation reverse transcriptase gene induced high level phenotypic resistance ( 5 ) . Similarly , Nevirapine use combination single nucleoside , incomplete suppression viral replication , resistance emerge non-nucleoside reverse transcriptase inhibitor ( 6 ) . In contrast , use part triple antiretroviral combination successful inhibition viral replication &lt; 50 copies/ml , viral response maintain 50 % patient 48 week ( 7 , 8 , 9 , 10 ) . However , virologic control lose , resistance Nevirapine emerge rapidly 50-100 % patient ( 11 ) . It unclear whether mutation develop initial suppression viral load replication rebound viremia failure . Given pharmacokinetics Nevirapine pregnant woman infant , concern raise mother child would expose Nevirapine monotherapy one several day selection resistant mutant could arise limit strategy long term . In fact , recent sub-analysis HIVNET 012 cohort find Nevirapine resistant mutation 21/111 ( 19 % ) woman test 6-8 week delivery . The K103N common mutation . Women high baseline viral load develop mutation frequently . Nevirapine resistant mutation also detect 11/24 ( 46 % ) infect infant 6-8 week . In contrast mother , Y181C commonly detect . Similarly , K103N resistance mutation detect 6 week Nevirapine administration 3/15 ( 20 % ) woman HIVNET006 phase I/II trial . This Nevirapine dosing schedule HIVNET012 ( 12 ) . New information become available base recent post-marketing surveillance data clarify risk factor severe life threaten fatal hepatotoxicity nevirapine . Women CD4 count &gt; 250 cellsmm3 initiation therapy include pregnant woman receive chronic treatment HIV infection considerably high risk ( 12-fold ) hepatotoxicity case fatal . The great risk severe potentially fatal hepatic event occur first 6 week therapy . However , risk continue time patient closely monitor first 18 week therapy . For reason , woman CD4 &gt; 250/mm3 include Objective 1 study . Hypothesis Nevirapine resistance develop woman infant HIVNET 006 012 cohort consequence use agent long t½ monotherapy individual high viral load . Objective 1 To demonstrate Nevirapine resistance develop HIV infect patient use part triple antiretroviral combination therapy initiation treatment suppression HIV RNA &lt; 1000 copies/ml . Objective 2 To demonstrate resistance nevirapine develop patient suppress HIV RNA discontinue combination antiretroviral therapy contain nevirapine .</detailed_description>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria ( Objective 1 ) 1 . HIV infect adult 2 . Antiretroviral naïve 3 . Viral load &gt; 1000 copies/ml 4 . Initiating combination antiretroviral therapy , include nevirapine . Exclusion Criteria ( Objective 1 ) 1 . Women CD4 count &gt; 250/mm3 Inclusion Criteria ( Objective 2 ) 1 . HIV infect adult 2 . On initial ARV combination contain nevirapine 3 . HIV RNA &lt; 50 copies/ml 4 . Decision discontinue ARV therapy completion pregnancy drug holiday 5 . Not resistant nevirapine . Note since patient meet criterion Objective 1 expect achieve HIV RNA &lt; 50 copies/mL , patient population Objectives 1 2 almost .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>